Alice Y. Chang, M.D., M.S.

The purpose of this study is to create a patient-centered research partnership with a stakeholder advisory group (SAB) to adapt the Duke Transgender and Gender Diverse Individual Registry. The SAB will guide all phases of the proposed research to develop a framework for the first US multisite adult TGD prospective cohort. Patient registries are one of the most effective research tools for studying and understanding underrepresented populations and rare diseases. They support quality measurement, provide feedback to clinicians and institutions for quality improvement, facilitate clinical research, and enable evaluation of healthcare access and disparities.    

The purpose of this study is to evaluate the effectiveness and safety of  ATR-101 for the treatment of adults who have internally caused Cushings syndrome.

This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.

The purpose of this study is to evaluate the blood chemistry, genetics, and eye exams in women with polycystic ovary syndrome and/or intracranial hypertension. Similar studies are being completed with astronauts. The results may help us better understand the nature, and ultimately the treatment of polycystic ovary syndrome, intracranial hypertension, and astronaut eye and vision issues.

The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's effect on insulin sensitivity and endothelial function. This pilot project will be the foundation for developing tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug targets.